Law360, New York (July 12, 2012, 3:14 PM ET) -- GlaxoSmithKline PLC has withdrawn its supplemental application to the U.S. Food and Drug Administration seeking approval to combine its breast cancer drug Tykerb with Roche Holding AG's rival drug Herceptin because of insufficient clinical data, the drugmaker said Wednesday.
GSK, which filed its supplemental new drug application for using Tykerb in combination with Herceptin for the treatment of patients with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin in February, said it would wait for the results of ongoing studies testing the drug...
GSK Yanks Bid To Combine Tykerb With Roche's Herceptin
To view the full article, take a free trial now.
